Business
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing
About this update from Medicus Pharma Ltd.
[{"type":"text","content":"Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company\"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its subsidiary, Antev Ltd., has entered into Amendment No. 3 to its license agreement with LifeArc relating to Teverelix, an investigational next generation long-acting GnRH antagonist. Under the amended agreement, the royalty rate payable on worldwide net sales of Teverelix has been reduced from ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The amendment does not alter the scope of the license, the underlying intellectual property, or the respective development responsibilities of the parties, and all other terms of the original agreement remain in full force and effect. “This amendment substantially improves the long-term economic profile of Teverelix while preserving the strength and integrity of the underlying license,” stated Dr. Raza Bokhari, Medicus Exec. Chairman & CEO, “we believe the reduced royalty burden enhances Teverelix’s attractiveness for future partnering, especially for late-stage development and commercialization.” The original license grants exclusive, worldwide rights to develop, manufacture, and commercialize Teverelix across all major global markets, with full rights to grant sublicenses, including through multiple tiers, supporting flexible global partnering strategies. Medicus maintains full operational control over development, manufacturing, and commercialization activities, enabling efficient execution and streamlined decision-making. Under the license framework, all program-specific improvements and enhancements developed by Medicus, and its affiliates are owned by Medicus, supporting continued expansion of the Teverelix intellectual property estate a...